新型冠状病毒肺炎患者的综合药学照护  

Comprehensive pharmaceutical care for COVID-19

作　　者：李秦川[1] 谢方晴 郭西芮 姜倩 王洪菊 刘春[1] 叶永琴[1] LI Qin-chuan;XIE Fang-qing;GUO Xi-rui;JIANG Qian;WANG Hong-ju;LIU Chun;YE Yong-qin(Department of Clinical Pharmacy,Chengdu Second People's Hospital,Sichuan Chengdu 610017,China)

机构地区：[1]成都市第二人民医院临床药学科,四川成都610017

出　　处：《中国医院药学杂志》2020年第6期626-631,共6页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨新型冠状病毒肺炎(COVID-19)患者的药学监护模式。方法:采用文献研究法,结合综合药学照护方法,搜集、分析COVID-19病例临床特征,为建立分级药学监护及重点药学监护对象提供支持。结果:根据研究标准,最终纳入10篇文献及40例死亡病例研究。文献研究结果显示合并疾病为高血压、心血管疾病、糖尿病、呼吸系统疾病的重症患者多于非重者患者(P<0.001)。死亡病例中合并高血压疾病的患者占35%。以此提出分级药学监护标准、主要监护项目和具体实施细则。并对使用降压药、糖皮质激素、免疫球蛋白、肿瘤用药的患者进行重点药学监护分析。结论:新型冠状病毒肺炎疫情药学监护是一项专业性强的系统性工程,需要持续改进、不断完善、有序推进。OBJECTIVE To explore the pharmaceutical care mode of patients with COVID-19.METHODS The clinical characteristics of COVID-19 cases were collected and analyzed by literature research method combined with comprehensive pharmaceutical care method,providing support for the establishment of graded pharmaceutical care and key pharmaceutical care objects.RESULTS According to the research criteria,10 literature studies and 40 death cases were included.The results of literature research showed that the patients with hypertension,cardiovascular disease,diabetes and respiratory diseases were more severe than those without these underlying diseases(P<0.001).Among the deaths,35%were associated with hypertensive disorders.Based on this,the grading pharmaceutical care standards,main monitoring items and specific implementing rules are proposed.Key pharmaceutical care was also analyzed for patients using antihypertensive drugs,glucocorticoids,immunoglobulins,and oncology drugs.CONCLUSION Pharmaceutical care of COVID-19 is a professional and systematic project,which needs continuous improvement and orderly promotion.

关 键 词：新型冠状病毒肺炎 分级药学监护 合并疾病 

分 类 号：R952[医药卫生—药学]